The Medical Advisor

Quick Answer:  The most consequential 2026 cancer breakthrough is daraxonrasib , an oral RAS(ON) inhibitor that nearly doubled overall survival in previously treated metastatic pancreatic cancer in the phase 3 RASolute 302 trial presented at ASCO 2026. Other major advances include the OPTIMA trial , showing many high-risk breast cancer patients can safely skip chemotherapy after genomic testing; the bispecific antibody ivonescimab , which outperformed standard immunotherapy in squamous lung cancer; continued expansion of CAR-T and cell therapies into solid tumors; and growing, evidence-tiered interest in repurposed drugs and metabolic approaches as complementary strategies. AACR 2026 and ASCO 2026 both emphasized that progress is driven by combining precision diagnostics, immunotherapy, and targeted agents — not a single cure. Despite  trillions spent on cancer research  ( The Lancet Oncology ), cancer still  kills around 10 million people a year  ( WHO )...

Cancer treatment is no longer one-dimensional. For decades, chemotherapy dominated oncology.  Today, treatment may include chemotherapy, targeted therapy, immunotherapy — or carefully designed combinations of all three. Yet confusion persists. Patients often ask: Is chemotherapy outdated? Is immunotherapy safer? Is targeted therapy more effective? Why do some people respond dramatically while others do not? This guide explains the science, clinical evidence, benefits, risks, and real-world decision-making framework behind modern oncology — grounded in standards used by the National Comprehensive Cancer Network and the American Society of Clinical Oncology. What is immunotherapy? Cancer cells are abnormal cells that replicate uncontrollably. Normally, your immune system destroys abnormal cells, but many types of cancer ce...